A Phase II Study Evaluating Reduced Starting Dose and Dose Escalation of Cabozantinib as Second-line Therapy for Advanced HCC in Patients With Preserved Liver Function
Latest Information Update: 29 Dec 2023
At a glance
- Drugs Cabozantinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms CaboRISE
- 21 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 21 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 21 Dec 2023 Status changed from recruiting to active, no longer recruiting.